Recombinant Mouse L-dopachrome tautomerase (Dct), partial

In Stock
Code CSB-EP006562MO1
Size $306
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 90% as determined by SDS-PAGE.
Target Names
Dct
Uniprot No.
Research Area
Cell Biology
Alternative Names
Dct; Tyrp-2; Tyrp2; L-dopachrome tautomerase; DCT; DT; EC 5.3.3.12; DOPAchrome conversion factor; DOPAchrome isomerase; DOPAchrome oxidoreductase; L-dopachrome Delta-isomerase; SLATY locus protein; Tyrosinase-related protein 2; TRP-2; TRP2
Species
Mus musculus (Mouse)
Source
E.coli
Expression Region
24-472aa
Target Protein Sequence
QFPRVCMTLDGVLNKECCPPLGPEATNICGFLEGRGQCAEVQTDTRPWSGPYILRNQDDREQWPRKFFNRTCKCTGNFAGYNCGGCKFGWTGPDCNRKKPAILRRNIHSLTAQEREQFLGALDLAKKSIHPDYVITTQHWLGLLGPNGTQPQIANCSVYDFFVWLHYYSVRDTLLGPGRPYKAIDFSHQGPAFVTWHRYHLLWLERELQRLTGNESFALPYWNFATGKNECDVCTDELLGAARQDDPTLISRNSRFSTWEIVCDSLDDYNRRVTLCNGTYEGLLRRNKVGRNNEKLPTLKNVQDCLSLQKFDSPPFFQNSTFSFRNALEGFDKADGTLDSQVMNLHNLAHSFLNGTNALPHSAANDPVFVVLHSFTDAIFDEWLKRNNPSTDAWPQELAPIGHNRMYNMVPFFPPVTNEELFLTAEQLGYNYAVDLSEEEAPVWSTTLS
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
69.7kDa
Protein Length
Partial
Tag Info
N-terminal 10xHis-SUMO-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

 Q&A
Q:

I have a few more questions for you concerning this order:
1. Can we get the non-tagged protein with same purification rate for catalogue product (>90%) ?
2. If the purification rate is less than 90%, can you continue purification process to achieve >90%?
3. What is the isoelectric point?
4. Regarding as lyophilized process, what components is including in the product? We would like to know whether there is some glycerol, sodium or detergents.
5. What is the smallest packing size.
6. Could you tell us the result of small scale expression before complete main production when we receive the order?

A:
Thanks for your inquiry. Here are answers to your questions.
1. Our quality control standards of the protein is higher than 85% as determined by SDS-PAGE. It is not guaranteed that it can reach 90%.
2. There will be more loss of protein for further purification, and it is more difficult to further increase the purity of this no-tagged protein. Considering these two reasons, we will not continue to purify when it reach to our quality control standards.
3. Predicted theoretical pl of this protein is 5.87.
4. Buffer before lyophilization is 10mM Tris-HCI, 1mM M EDTA, pH 8.0. There is no glycerol, sodium or detergents in the lyophilized protein.
5. Regarding this case, our default packing size is 1mg *50vials if you don't have special request. And we could provide 10ug/50ug/100ug/200ug/500ug1mg as well. Pls let us know if you have special request of package.
6. As we mentioned before, we've been working on this case since we got your further inquiry. We've succeeded in removing the tag and the restult of small scale expression is good. So we can make sure to provide 50mg at once.
Q:

1) The concentration of this protein is 0.6725 mg/mL before freeze-drying treatment. Is it upper limit of the concentration? I would like to use the protein at a higher concentration.
2) I performed SDS-PAGE at high concentration, but I could not get sharp band. The result shows rather than a ladder bands, like spreading wide, not sharp. I can obtain a clear band at a lower concentration (< 0.6725 mg/mL). As a matter of my experiment, I would like to analyze the protein by SDS-PAGE at high concentration. Could you please advise me to get sharp band at high concentration?
3) Could you please tell me the stability of proteins in water?
4) Have you investigated the isoelectric point of this protein? Furthermore, Is there a difference between CSB-EP006562MO1e1(No tag) and CSB-EP006562MO1(His tag) in the isoelectric point?
5) Could you please provide me with the information regarding the physical properties (e.g. solubility in water or buffer etc...)?

A:
Thanks for your inquiry. Our replies are as below.
1)The lyophilized powder was quantified before lyophilization (liquid state). The protein was measured by the Bradford method, concentration of the protein is 0.6725 mg/ml.
Then according to the package requirements, protein was put into different vials. Just as shown in the COA, (Lyophilized from 10 mM Tris-HCl, 1 mM EDTA, pH 8.0. The volume before lyophilization is 15 ul / vial, 20vial; 75 ul / vial, 20vial; 145 ul / Vial,48vial;720 ul/vial,68vial;1440 ul/vial,10vial)
For example, 10 ug tube: 0.6725 mg/ml*15 ul=10.08 ug. It is the amount of target protein.
2)Freeze-drying only evaporates the water and the ions are not lost. So the lyophilized powder also contains Tris-HCl, EDTA only. It does not contain glycerin, salt, detergent, or any other substances.
3)However, the different volume of reconstituted solution will lead to the difference of its buffer pH and its ionic strength. Therefore, if you want the same ionic concentration and pH before and after lyophilization, you could use deionized sterile water (same volume as before lyophilization) to redissolve.
PS: (If you want to calculate the mass of Tris-HCl, EDTA in each tube, it can be calculated according to the formula (m=c.v.M) where v: the volume before lyophilization)
If the SDS-PAGE is not clear, consider increasing the time of the sample, or prolong the decolorization time, while optimizing the amount of sample loading.
Our running parameters are: Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel, provided for your reference.

Target Background

Function
Catalyzes the conversion of L-dopachrome into 5,6-dihydroxyindole-2-carboxylic acid (DHICA).
Gene References into Functions
  1. soyasaponin Ag inhibited TRP2 expression in a dosedependent manner. Therefore, the depigmenting effect of soyasaponin Ag may be due to the inhibition of tyrosinase expression or the enhancement of tyrosinase degradation. PMID: 28713957
  2. the slaty mutant melanocytes seem to be more sensitive to ultraviolet rays and oxidative stress than black melanocytes. PMID: 26451690
  3. A novel murine model of vitiligo is established by sequential prime/boost immunizations into the hind footpad and tail dermis with tyrosinase-related protein 2 (TRP2)-180 (SVYDFFVWL) peptide. PMID: 23711243
  4. study indicates that tumor antigen (TRP2) expressed in MCMV induces a strong and long-lasting anti-melanoma effect through an antibody-dependent mechanism PMID: 23811402
  5. Vaccine formulations with synthetic long peptides for treating B16F10 skin melanoma fails to elicit strong CD8 T cell responses to self-differentiation antigens TRP-2 and gp100. PMID: 23203930
  6. level of gene targeting was not improved by the DSB induction, indicating a limited capacity of I-SceI to mediate homologous recombination at the Dct locus PMID: 22761925
  7. Recombinant dopachrome tautomerase was expressed and purified, without its carboxy-terminal transmembrane region. Analysis of dopachrome tautomerase tryptic peptides by MALDI-TOF/TOF determined N-glycosylation as a primary post-translational modification. PMID: 20386969
  8. Dopachrome tautomerase inactivation elevates the level of ROS, increases the numbers of sunburn cells and apoptotic cells, and decreases the amount of eumelanin in the epidermis upon exposure to chronic UVA radiation PMID: 20123016
  9. the TRP-2 polypeptide folds in the endoplasmic reticulum (ER) in the presence of calnexin, until it reaches a dithiothreitol-resistant conformation enabling its ER exit to the Golgi PMID: 12719423
  10. Results describe the generation of a knockout of the dopachrome tautomerase gene in mice with effects restricted to pigment production and coat color. PMID: 15060160
  11. We found that ionophore monensin (Mon) and the quaternary amine chloroquine (CQ) discriminate between the traffic routes of TRP-2 and TRP-1 PMID: 15707965
  12. The enzymatic activity of Dct may play a role in determining whether the eumelanin or pheomelanin pathway is preferred for pigment biosynthesis. PMID: 15960609
  13. These results suggest that the slaty mutation affects both eumelanin and pheomelanin synthesis in developmental stage-specific and skin site-specific manners. PMID: 16584806
  14. Slaty mutation blocks the melanosome maturation at stage III and affects the melanosome morphology (elliptical or spherical) in a developmental stage-specific manner. PMID: 17516460
  15. Eumelanin and pheomelanin may accumulate with difficulty in slaty-mutated melanocytes and be easily released from them during skin development. L-Tyr may stimulate this release. PMID: 17551240
  16. These results suggest that the slaty mutation inhibits the development of elliptical stage IV melanosomes and that L-Tyr restores the development of elliptical stage IV melanosomes PMID: 17867832
  17. Cytotoxicity toward targets loaded with a K(b)-restricted tyrosinase-related protein 2-derived peptide correlated with depigmentation in a mouse model of autoimmune vitiligo. PMID: 18337834
  18. mice lacking DCT displayed normal cardiac development but an increased susceptibility to atrial arrhythmias PMID: 19855129

Show More

Hide All

Involvement in disease
The slaty mutation in Tyrp2 leads to a decrease of DT activity and a consequent change in the pigmentation of the mice to a dark gray/brown eumelanin. The slaty-2j mutation has a similar phenotype, the slaty-lt (light) mutation has a more severe effect and is semidominant; its phenotype may be a result of the failure of the enzyme to be correctly targeted to its normal location on the inner face of the melanosomal membrane.
Subcellular Location
Melanosome membrane; Single-pass type I membrane protein. Melanosome.
Protein Families
Tyrosinase family
Tissue Specificity
Melanocytes and retinal pigmented epithelium (at protein level).
Database Links
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*